Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature

YILMAZ M., Eskazan A. E. , UNSAL A., TANINMIS H. , KARA E. , CETINER M., ...Daha Fazla

TRANSFUSION, cilt.53, ss.1586-1593, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier


BackgroundThrombotic thrombocytopenic purpura (TTP) is a life-threatening disease, characterized by microangiopathic hemolytic anemia, thrombocytopenia, fever, neurologic disturbances, and renal failure. Plasma therapy has dramatically improved prognosis of TTP, whereas recurrent acute episodes still occur in approximately 40% of patients. Moreover, patients with acquired ADAMTS13 deficiency, which is a significant factor for relapse, may require additional immunosuppressive treatment to get a durable remission.